Literature DB >> 26614866

Myelodysplastic Syndromes and Acute Myeloid Leukemia in the Elderly.

Heidi D Klepin1.   

Abstract

Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are hematologic diseases that frequently affect older adults. Treatment is challenging. Management of older adults with MDS and AML needs to be individualized, accounting for both the heterogeneity of disease biology and patient characteristics, which can influence life expectancy and treatment tolerance. Clinical trials accounting for the heterogeneity of tumor biology and physiologic changes of aging are needed to define optimal standards of care. This article highlights key evidence related to the management of older adults with MDS and AML and highlights future directions for research.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acute myeloid leukemia; Elderly; Management; Myelodysplasia; Older; Treatment

Mesh：

Year:  2016        PMID： 26614866      PMCID： PMC4664149          DOI： 10.1016/j.cger.2015.08.010

Source DB:  PubMed          Journal:  Clin Geriatr Med        ISSN： 0749-0690            Impact factor:   3.076


  66 in total

1.  Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.

Authors:  Pierre Fenaux; Ghulam J Mufti; Eva Hellström-Lindberg; Valeria Santini; Norbert Gattermann; Ulrich Germing; Guillermo Sanz; Alan F List; Steven Gore; John F Seymour; Hervé Dombret; Jay Backstrom; Linda Zimmerman; David McKenzie; C L Beach; Lewis R Silverman
Journal:  J Clin Oncol       Date:  2009-12-21       Impact factor: 44.544

2.  Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia.

Authors:  Anne Etienne; Benjamin Esterni; Aude Charbonnier; Marie-Joëlle Mozziconacci; Christine Arnoulet; Diane Coso; Brigitte Puig; Jean-Albert Gastaut; Dominique Maraninchi; Norbert Vey
Journal:  Cancer       Date:  2007-04-01       Impact factor: 6.860

3.  High-dose daunorubicin in older patients with acute myeloid leukemia.

Authors:  Bob Löwenberg; Gert J Ossenkoppele; Wim van Putten; Harry C Schouten; Carlos Graux; Augustin Ferrant; Pieter Sonneveld; Johan Maertens; Mojca Jongen-Lavrencic; Marie von Lilienfeld-Toal; Bart J Biemond; Edo Vellenga; Marinus van Marwijk Kooy; Leo F Verdonck; Joachim Beck; Hartmut Döhner; Alois Gratwohl; Thomas Pabst; Gregor Verhoef
Journal:  N Engl J Med       Date:  2009-09-24       Impact factor: 91.245

Review 4.  Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis.

Authors:  Victor Moyo; Patrick Lefebvre; Mei Sheng Duh; Behin Yektashenas; Suneel Mundle
Journal:  Ann Hematol       Date:  2008-03-20       Impact factor: 3.673

5.  Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs.

Authors:  Dana E Rollison; Nadia Howlader; Martyn T Smith; Sara S Strom; William D Merritt; Lynn A Ries; Brenda K Edwards; Alan F List
Journal:  Blood       Date:  2008-04-28       Impact factor: 22.113

6.  Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia.

Authors:  Arati V Rao; Peter J M Valk; Klaus H Metzeler; Chaitanya R Acharya; Sascha A Tuchman; Marvaretta M Stevenson; David A Rizzieri; Ruud Delwel; Christian Buske; Stefan K Bohlander; Anil Potti; Bob Löwenberg
Journal:  J Clin Oncol       Date:  2009-10-26       Impact factor: 44.544

7.  Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials.

Authors:  Keith Wheatley; Cassandra L Brookes; Andrew J Howman; Anthony H Goldstone; Donald W Milligan; Archibald G Prentice; Anthony V Moorman; Alan K Burnett
Journal:  Br J Haematol       Date:  2009-03-26       Impact factor: 6.998

8.  Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia.

Authors:  Jean-Valère Malfuson; Anne Etienne; Pascal Turlure; Thierry de Revel; Xavier Thomas; Nathalie Contentin; Christine Terré; Sophie Rigaudeau; Dominique Bordessoule; Norbert Vey; Claude Gardin; Hervé Dombret
Journal:  Haematologica       Date:  2008-10-06       Impact factor: 9.941

9.  Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome.

Authors:  Martin Jädersten; Luca Malcovati; Ingunn Dybedal; Matteo Giovanni Della Porta; Rosangela Invernizzi; Scott M Montgomery; Cristiana Pascutto; Anna Porwit; Mario Cazzola; Eva Hellström-Lindberg
Journal:  J Clin Oncol       Date:  2008-06-16       Impact factor: 44.544

10.  Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia.

Authors:  Sebastian Scholl; Claudia Theuer; Veit Scheble; Christa Kunert; Anita Heller; Lars-Olof Mügge; Hans-Joerg Fricke; Klaus Höffken; Ulrich Wedding
Journal:  Eur J Haematol       Date:  2008-03       Impact factor: 2.997
View more
  11 in total

1.  Reticular Skin Rash as an Adverse Effect of 5-Azacitidine.

Authors:  Parul Verma; Usha Chandra; Prakriti Shukla; Shailendra P Verma; Swastika Suvirya
Journal:  Cureus       Date:  2022-04-18

2.  Novel inhibitor of hematopoietic cell kinase as a potential therapeutic agent for acute myeloid leukemia.

Authors:  Fernanda Marconi Roversi; Maura Lima Pereira Bueno; Juliete Aparecida Francisco da Silva; Guilherme Rossi Assis-Mendonça; Cristiane Okuda Torello; Rodrigo Nato Shiraishi; Fernando Viera Pericole; Karla Priscila Ferro; Adriana Santos Silva Duarte; Eduardo Magalhães Rego; Sara Teresinha Olalla Saad
Journal:  Cancer Immunol Immunother       Date:  2022-01-18       Impact factor: 6.630

3.  Effect of Chinese medicine treatment based on pattern identification on cellular immunophenotype of myelodysplastic syndrome.

Authors:  Yu Zhang; Li-Li Qian; Jian-Ping Shen; Jun-Fa Chen; Yan-Ting Gao; Jing-Jing Xiang; Bao-Dong Ye; Yu-Hong Zhou
Journal:  Chin J Integr Med       Date:  2016-12-09       Impact factor: 1.978

4.  TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.

Authors:  John S Welch; Allegra A Petti; Christopher A Miller; Catrina C Fronick; Michelle O'Laughlin; Robert S Fulton; Richard K Wilson; Jack D Baty; Eric J Duncavage; Bevan Tandon; Yi-Shan Lee; Lukas D Wartman; Geoffrey L Uy; Armin Ghobadi; Michael H Tomasson; Iskra Pusic; Rizwan Romee; Todd A Fehniger; Keith E Stockerl-Goldstein; Ravi Vij; Stephen T Oh; Camille N Abboud; Amanda F Cashen; Mark A Schroeder; Meagan A Jacoby; Sharon E Heath; Kierstin Luber; Megan R Janke; Andrew Hantel; Niloufer Khan; Madina J Sukhanova; Randall W Knoebel; Wendy Stock; Timothy A Graubert; Matthew J Walter; Peter Westervelt; Daniel C Link; John F DiPersio; Timothy J Ley
Journal:  N Engl J Med       Date:  2016-11-24       Impact factor: 91.245

Review 5.  Targeting Metabolic Reprogramming in Acute Myeloid Leukemia.

Authors:  Isabel Castro; Belém Sampaio-Marques; Paula Ludovico
Journal:  Cells       Date:  2019-08-24       Impact factor: 6.600

Review 6.  Understanding intrinsic hematopoietic stem cell aging.

Authors:  Eva Mejia-Ramirez; Maria Carolina Florian
Journal:  Haematologica       Date:  2019-12-05       Impact factor: 9.941

7.  Targeting, Monitoring and Effect of Oral Iron Therapy on Haemoglobin Levels in Older Patients Discharged to Primary Care from Inpatient Rehabilitation: A Cohort Study Using Routinely Collected Data.

Authors:  Zach Thomson; Katherine J Hands; Miles D Witham
Journal:  Drugs Aging       Date:  2016-08       Impact factor: 3.923

8.  The synergistic antileukemic effects of eltrombopag and decitabine in myeloid leukemia cells.

Authors:  Mingyue Shi; Fangfang Xu; Xiawan Yang; Yanliang Bai; Junwei Niu; Emmanuel Kwateng Drokow; Mingyi Chen; Yuqing Chen; Kai Sun
Journal:  Cancer Manag Res       Date:  2019-09-06       Impact factor: 3.989

Review 9.  The Interplay Between the Genetic and Immune Landscapes of AML: Mechanisms and Implications for Risk Stratification and Therapy.

Authors:  Lourdes M Mendez; Ryan R Posey; Pier Paolo Pandolfi
Journal:  Front Oncol       Date:  2019-11-07       Impact factor: 6.244

10.  Using Social Media to Uncover Treatment Experiences and Decisions in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Who Are Ineligible for Intensive Chemotherapy: Patient-Centric Qualitative Data Analysis.

Authors:  Alison Booth; Timothy Bell; Sonia Halhol; Shiyu Pan; Verna Welch; Evie Merinopoulou; Dimitra Lambrelli; Andrew Cox
Journal:  J Med Internet Res       Date:  2019-11-22       Impact factor: 5.428
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.